Qizhi laser recently issued a semi annual report for 2022. The report shows that Qizhi laser achieved a revenue of 120 million yuan in the first half of this year, an increase of 8.42% year-on-year; The net profit attributable to the shareholders of the listed company was 17.73 million yuan, a year-on-year decrease of 19.47%.
1、 Main business
Qizhi laser is a high-tech enterprise in the medical device industry. It is a leading optoelectronic medical and beauty solution provider integrating R & D, production, agency and sales in China. It has undertaken more than 10 national and local key optoelectronic medical projects.
The company holds a medical device production license and a medical device business license. Its main products include laser medical and beauty equipment for skin treatment, beauty and urology.
As of the first half of this year, the company has held 20 medical device product registration certificates, obtained 68 patents (including one American patent), obtained ISO9001 and ISO13485 quality system certification, and some products have also passed the EU CE certification.
Qizhi laser has an independent and complete R & D, production, procurement and sales system and a mature business model. The technology center of the company is responsible for the development of new products. The R & D team has many years of technology accumulation and rich experience. It has independently developed and designed many high-performance laser, photoelectric medical and beauty equipment.
The company adopts the procurement mode of "order based plus safety inventory and on-demand procurement"; The production mainly adopts the order production method. At the same time, according to the market forecast, the production and stock preparation of some products are carried out to meet the requirements of basic inventory; The sales of the company adopts the direct sales and dealer mode, and some export products are sold through dealers. The customers mainly include public hospitals at all levels, private medical institutions, medical device distribution enterprises and beauty agencies.
2、 Business plan
In the first half of this year, the net profit of Qizhi laser decreased due to the influence of external factors such as COVID-19 and Sino US trade war. However, Qizhi laser said that it would continue to adhere to technological innovation, attach importance to R & D investment, strengthen internal operation, expand sales market, and strive to enhance the profitability of its main business.
In the first half of 2022, Qizhi laser invested 6.73 million yuan in R & D, accounting for 5.63% of the operating income. At the same time, it obtained 1 approval for the change of medical device registration certificate and 1 renewal of medical device registration certificate issued by the State Drug Administration, 2 renewal of medical device registration certificate and 1 approval for the change of medical device issued by Hubei drug administration. Qizhi laser said that in the future, the company will continue to pay attention to R & D investment and enhance the comprehensive competitiveness of the enterprise.
The report points out that in the first half of the year, the company's management team was stable and able to maintain good independent operation ability. Meanwhile, the company continued to strengthen the construction of service system, which made the marketing channels more diversified. Qizhi laser said that in the second half of 2022, the company will further integrate advantageous resources, introduce R & D talents, improve R & D technology, and continuously improve the company's business advantages through technological innovation and service innovation to promote the company's sustainable development.
3、 Industry situation
The medical device industry is an important part of the construction of China's medical and health service system. Because laser is superior to traditional treatment methods in terms of accuracy, efficacy and safety, many laser medical devices have been applied in various clinical departments, which can perform surgery or interventional treatment by coagulation, cutting and vaporization of pathological tissues to achieve clinical treatment effects.
Source: OFweek
